Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment

NEW YORK, NY--(Marketwired - Jun 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational...
June 04, 2014 08:30 ET | Source: Nuvilex, Inc.

Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview

NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
May 23, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients

NEW YORK, NY--(Marketwired - May 23, 2014) - Nuvilex (OTCQB: NVLX) is calling it a "two pronged attack" on pancreatic cancer, but investors may be calling it an "end-around" or another avenue of...
April 03, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist

NEW YORK, NY--(Marketwired - Apr 3, 2014) - That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it...